Just for clarification the research by Wilton and Fletcher which led to the development of a therapy for DMD was conducted at The University of WA. I understand that the licensing agreement to develop exon-skipping drugs for DMD was signed between Sarepta and the UWA. The financial terms of that landmark agreement may hold some significance in looking at commercial deals between biotechnology companies and academic institutions.
Its a small world, page-2
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
